scholarly journals A Conceptual Study of Upanaha Swedana

AYUSHDHARA ◽  
2021 ◽  
pp. 3359-3361
Author(s):  
Avvinish Narine ◽  
Minu Yadav
Keyword(s):  
Digital Libraries ◽  
Treatment Modality ◽  
Standard Treatment ◽  
Data Types ◽  
Therapeutic Procedures ◽  
Conceptual Study ◽  
Medicinal Drugs ◽  
Localized Treatment ◽  
Post Therapy ◽  
Topical Analgesic

Swedana Karma is undertaken by inducing sweating from the application of heat. There are many methods used to achieve this, with Upanaha Swedana being one of them. Upanaha Swedana is a standard treatment modality used in Ayurveda for the management of pain and inflammation. It is a localized treatment wherein a combination of medicinal drugs are prepared, made into a poultice, heated and applied at the affected site. This is meant to reduce the local inflammation and act as a topical analgesic. The procedure is divided into three phases which are: Purva Karma (pre-therapy procedures), the preparation of the Upanaha Swedana material is done, Pradhana Karma (main therapeutic procedures) the prepared Upanaha Swedana material is applied to the patient and Paschat Karma (post-therapy procedures) after waiting the specified times, the Upahana Swedana is removed following proper procedures. The present conceptual study was done based on the need of the day to elaborate the process of conducting Upanaha Swedana. For this, various Ayurvedic texts, digital libraries referencing Samhita were searched and the following headings were selected, types of data, types of reports and functionalities. This article seeks to explore this treatment modality and outline the general approach to be followed while conducting the procedure of Upanaha Swedana.

300 Years of Intramedullary Fixation – from Aztec Practice to Standard Treatment Modality

2000 ◽  
Vol 26 (5) ◽  
pp. 217-225 ◽  
Author(s):  
Ulf Knothe ◽  
Melissa L. Knothe Tate ◽  
Stephan M. Perren
Keyword(s):  
Treatment Modality ◽  
Standard Treatment ◽  
Intramedullary Fixation

Recurrent vulvar squamous cell carcinoma: An analysis of clinical outcomes by treatment modality including surgery, chemotherapy, and radiation.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18033-e18033
Author(s):  
Trish Dinh ◽  
Natalie Andrews Wright ◽  
Hari Iyer ◽  
Johanne I Weberpals
Keyword(s):  
Surgical Management ◽  
Treatment Modality ◽  
Standard Treatment ◽  
Treatment Options ◽  
Retrospective Chart Review ◽  
Primary Treatment ◽  
Outcome Data ◽  
Cancer Center ◽  
Real World Data ◽  
Significant Difference

e18033 Background: Recurrent VSCC carries a poor prognosis, but real-world data on outcomes with standard treatment options are lacking. Specifically, progression free survival (PFS) in recurrent VSCC is ill-defined which is problematic for the design of clinical trials with novel therapies. We aim to address the paucity of outcome data in recurrent VSCC and to compare PFS and overall survival (OS) in patients (pts) undergoing surgery, chemotherapy, radiotherapy or a combination of these treatments. Methods: A retrospective chart review identified 246 pts from 2000-2018 diagnosed with VSCC treated at the Ottawa Hospital Cancer Center and 61 pts with recurrent disease. Data collected included patient demographics, tumour characteristics, recurrence pattern, and treatment modality (surgery only, surgery with chemotherapy, surgery with radiation, surgery with chemoradiation, chemoradiation only, chemotherapy only, or radiation only). Descriptive statistical analysis is reported. Results: Among all study pts, the stage distribution was stage I: 28%, II: 19%, III: 43% and IV: 10%. 61% of pts had one recurrence, 36% had two recurrences, and 3% had three recurrences. The 5-year survival rate was 78% for non-recurrent VSCC vs. 33% for recurrent cases. The median OS for all recurrent and non-recurrent cases was 3.7 years and 13.5 years, respectively. For primary treatment, 87% underwent surgical treatment, of which 60% also had radiation or chemoradiation. The most common treatments for first recurrence were: surgery (25%), radiation (20%), no treatment (16%) and chemotherapy (14%), and for second recurrence: no treatment (50%), radiation (25%), surgery (17%) and chemotherapy (8%). The median PFS after primary treatment and after first and second recurrences were 8.7, 5.3 and 1.4 months (mo), respectively, with no significant difference between treatment regimens. However, when grouped (surgery with or without chemotherapy, radiation or chemoradiation vs. non-surgical management), there was a significant PFS benefit for surgical (15.6 mo) over non-surgical management (0.7 mo) in the treatment of a second recurrence (p = 0.05). Conclusions: At our centre, surgery and radiation have been the mainstay of treatment for recurrent VSCC with particular advantage of surgery in the treatment of a second recurrence. Our study establishes a baseline for VSCC outcomes following standard treatment. Accurate PFS data is an important outcome for the design of future studies in recurrent VSCC with new drug therapies.

Sign in / Sign up

Export Citation Format

Share Document